Axi-Cel

Kite Pharma Inc (NASDAQ: KITE) is preparing to launch Axi-Cel, a chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma patients, later this year. Kite is pursuing an FDA label for patients with relapsed, aggressive and non-transplant eligible forms of the disease, a group of...